search
Back to results

Improving Depression Outcome by Enhancing Memory for Cognitive Therapy

Primary Purpose

Major Depressive Disorder (MDD)

Status
Completed
Phase
Phase 2
Locations
United States
Study Type
Interventional
Intervention
Cognitive therapy for depression
Sponsored by
University of California, Berkeley
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Major Depressive Disorder (MDD) focused on measuring Depression, Adults

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • diagnosis of major depressive disorder (MDD), first episode, recurrent or chronic, according to DSM-IV-TR criteria
  • score of 24 or above on the Inventory of Depressive Symptomatology (IDS)-Clinician and 26 or above on the IDS-Self-report
  • older than 18 years of age
  • if taking medications for mood, medications must be stable for the past 4 weeks
  • able and willing to give informed consent

Exclusion Criteria:

  • history of bipolar disorder
  • history of psychosis (including schizophrenia, schizophreniform disorder, schizoaffective disorder, delusional disorder, or psychotic organic brain syndrome)
  • current non-psychotic Axis I disorder if it constitutes the principal diagnosis and if it requires treatment other than that offered in the project (including anxiety disorders including active PTSD, somatoform disorders, dissociative disorders, or eating disorders, etc.)
  • history of substance dependence in the past six months
  • IQ below 80
  • evidence of any medical disorder or condition that could cause depression or preclude participation in CT
  • current suicide risk sufficient to preclude treatment on an outpatient basis

Sites / Locations

  • University of California, Berkeley

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Active Comparator

Arm Label

Cognitive Therapy plus Cognitive Support

Cognitive therapy

Arm Description

Cognitive therapy for depression with cognitive support added

Cognitive therapy for depression

Outcomes

Primary Outcome Measures

Inventory of Depressive Symptomatology, Self Report (IDS-SR)
Primary mood outcome
Global Assessment of Functioning (GAF)
Primary impairment outcome

Secondary Outcome Measures

Structured Clinical Interview for DSM-IV (SCID)
To determine the presence or absence of current DSM-IV-TR defined episodes of depression
Longitudinal Interval Follow-up Evaluation (LIFE)
Time to relapse or recurrence
ACNP defined Response, Remission, Relapse, Recurrence using the IDS, SCID and LIFE

Full Information

First Posted
February 6, 2013
Last Updated
September 16, 2015
Sponsor
University of California, Berkeley
Collaborators
National Institute of Mental Health (NIMH), Vanderbilt University
search

1. Study Identification

Unique Protocol Identification Number
NCT01790919
Brief Title
Improving Depression Outcome by Enhancing Memory for Cognitive Therapy
Official Title
Improving Depression Outcome by Enhancing Memory for Cognitive Therapy
Study Type
Interventional

2. Study Status

Record Verification Date
September 2015
Overall Recruitment Status
Completed
Study Start Date
February 2013 (undefined)
Primary Completion Date
March 2015 (Actual)
Study Completion Date
March 2015 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
University of California, Berkeley
Collaborators
National Institute of Mental Health (NIMH), Vanderbilt University

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
Existing drug and talking therapies for major depressive disorder (MDD) fail to produce complete recovery. This study will determine if substantial improvements to one of the most promising therapies, cognitive therapy (CT), can be achieved by administering a carefully designed procedure to improve memory for the content of CT sessions. This is important because (a) memory deficits are common in MDD patients and (b) each CT therapy session typically covers a complex array of topics and various skills are taught.
Detailed Description
Background. Major depressive disorder (MDD) is one of the most prevalent psychiatric disorders and a leading cause of disability worldwide. Existing therapies fail to produce complete recovery. Progress toward improving outcome must include innovations that are safe, powerful, inexpensive and simple (for fast and effective dissemination). The proposed research seeks to test one such innovation. We seek to improve outcome by improving memory for the content of cognitive therapy (CT) sessions. CT is one of the most promising approaches to the treatment of MDD, yet there is room for improvement. We believe that adding memory enhancing strategies to CT may improve MDD outcome because: (a) MDD is often characterized by memory impairment, (b) there is evidence that the memory impairment is modifiable, (c) CT typically entails the activation of emotion, (d) emotion can impair or bias memory and (e) there is evidence that memory for the content of therapy sessions is poor. Aim. To evaluate if a strategy designed to enhance memory for the content of CT sessions improves treatment outcome for MDD. Cognitive support involves a series of specific procedures that support the encoding and retrieval stages of an episodic memory. It is hypothesized that CT+Cognitive Support, relative to CT-as-usual, will be associated with improved depression outcome at the end of treatment and 6 months after the completion of treatment. Research Plan. A small pilot feasibility RCT will be conducted on adults with MDD (n = 48) who will be randomized to one of two groups: (a) CT+Cognitive Support (n = 24) or (b) CT-as-usual (n = 24). Outcome measures will be taken at baseline, end of treatment, and 6 months after treatment. Long-term objective. To provide the pilot data needed to prepare a larger scale intervention study focused on improving outcomes by improving memory for the content of therapy sessions. The outcomes, if positive, will have major public health implications because simple, inexpensive memory enhancing strategies can be readily included as a standard feature in all psychosocial treatments for a broad range of mental illness. Project

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Major Depressive Disorder (MDD)
Keywords
Depression, Adults

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Parallel Assignment
Masking
ParticipantOutcomes Assessor
Allocation
Randomized
Enrollment
48 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Cognitive Therapy plus Cognitive Support
Arm Type
Experimental
Arm Description
Cognitive therapy for depression with cognitive support added
Arm Title
Cognitive therapy
Arm Type
Active Comparator
Arm Description
Cognitive therapy for depression
Intervention Type
Behavioral
Intervention Name(s)
Cognitive therapy for depression
Intervention Description
Cognitive therapy (CT) for depression. There is evidence that CT for major depressive disorder (MDD) can be as effective as antidepressant medication for the initial treatment of moderate to severe MDD. Moreover, following the withdrawal of treatment, patients treated with CT are significantly less likely to relapse than patients treated with antidepressant medication and CT is at least as effective as antidepressant medication in preventing subsequent relapse. Over 14 sessions CT aims to alter the symptomatic expression of depression and reduce risk for subsequent episodes by correcting the negative beliefs and maladaptive information processing presumed to underlie the disorder and alter the systematic tendency to misperceive reality in a pessimistic fashion. Cognitive support. An intervention to improve memory for the contents of therapy. Cognitive support involves a series of specific procedures that support the encoding and retrieval stages of an episodic memory.
Primary Outcome Measure Information:
Title
Inventory of Depressive Symptomatology, Self Report (IDS-SR)
Description
Primary mood outcome
Time Frame
Change in IDS scores from pre-treatment to post-treatment (defined as within 2 weeks of completing the course of treatment, which is 14 sessions) to 6-month followup
Title
Global Assessment of Functioning (GAF)
Description
Primary impairment outcome
Time Frame
Change in GAF scores from pre-treatment to post-treatment (defined as within 2 weeks of completing the course of treatment, which is 14 sessions) to 6-month followup
Secondary Outcome Measure Information:
Title
Structured Clinical Interview for DSM-IV (SCID)
Description
To determine the presence or absence of current DSM-IV-TR defined episodes of depression
Time Frame
Pre-treatment; Within 2 weeks of completing the course of treatment (14 sessions); 6 month followup
Title
Longitudinal Interval Follow-up Evaluation (LIFE)
Description
Time to relapse or recurrence
Time Frame
Pre-treatment; within 2 weeks of completing the course of treatment (14 sessions); 6-month followup
Title
ACNP defined Response, Remission, Relapse, Recurrence using the IDS, SCID and LIFE
Time Frame
Pre-treatment; within 2 weeks of completing the course of treatment (14 sessions); 6-month followup
Other Pre-specified Outcome Measures:
Title
Memory Support Rating Scale (MSRS).
Description
This is a measure of the use of memory support by treatment providers.
Time Frame
All patients receive 14 sessions of cognitive therapy for depression. The treatment sessions are video taped. A random subset of 20% of the tapes are selected for MSRS scoring. Average MSRS scores will be compared across the 2 groups.
Title
Patient Recall Task.
Description
This is a measure of the content of treatment that patient's remember
Time Frame
Completed at the end of Session 7, 14 and at 6 month FU. Patient Recall Task scores will be compared across the two treatment arms and over the three assessment points.
Title
National Adult Reading Test (NART).
Description
Estimate of IQ. Used to determine if IQ is a moderator of treatment.
Time Frame
This measure is taken at baseline (pre-treatment) and will be compared across the two treatment arms
Title
Episodic Face Naming Task.
Description
Measure of declarative memory. used to determine if baseline memory is a moderator of treatment outcome.
Time Frame
This measure is taken at baseline (pre-treatment) and will be compared across the two treatment arms
Title
Cognitive Therapy Rating Scale (CTRS)
Description
Measure of the quality of cognitive therapy
Time Frame
CTRS coding will be conducted on randomly selected recordings of treatment sessions. Average CTRS scores will be compared across the two treatment arms
Title
Credibility/Expectancy Questionnaire (CEQ)
Description
A measure of treatment expectancies
Time Frame
The CEQ scores, measured at the end of the first therapy session, will be compared across the two treatment arms
Title
Demographics form
Description
Assesses demographics including age, years of education and chronicity of depression that are used in moderator analysis
Time Frame
This measure is taken at baseline (pre-treatment) and will be compared across the two treatment arms

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: diagnosis of major depressive disorder (MDD), first episode, recurrent or chronic, according to DSM-IV-TR criteria score of 24 or above on the Inventory of Depressive Symptomatology (IDS)-Clinician and 26 or above on the IDS-Self-report older than 18 years of age if taking medications for mood, medications must be stable for the past 4 weeks able and willing to give informed consent Exclusion Criteria: history of bipolar disorder history of psychosis (including schizophrenia, schizophreniform disorder, schizoaffective disorder, delusional disorder, or psychotic organic brain syndrome) current non-psychotic Axis I disorder if it constitutes the principal diagnosis and if it requires treatment other than that offered in the project (including anxiety disorders including active PTSD, somatoform disorders, dissociative disorders, or eating disorders, etc.) history of substance dependence in the past six months IQ below 80 evidence of any medical disorder or condition that could cause depression or preclude participation in CT current suicide risk sufficient to preclude treatment on an outpatient basis
Facility Information:
Facility Name
University of California, Berkeley
City
Berkeley
State/Province
California
ZIP/Postal Code
94720
Country
United States

12. IPD Sharing Statement

Citations:
PubMed Identifier
35963181
Citation
Dong L, Zieve G, Gumport NB, Armstrong CC, Alvarado-Martinez CG, Martinez A, Howlett S, Fine E, Tran M, McNamara ME, Weaver C, Tuck AB, Hilmoe HE, Agnew E, Fisher K, Diaz M, Lee JY, Hollon SD, Notsu H, Harvey AG. Can integrating the Memory Support Intervention into cognitive therapy improve depression outcome? A randomized controlled trial. Behav Res Ther. 2022 Oct;157:104167. doi: 10.1016/j.brat.2022.104167. Epub 2022 Aug 6.
Results Reference
derived
PubMed Identifier
29137655
Citation
Harvey AG, Dong L, Lee JY, Gumport NB, Hollon SD, Rabe-Hesketh S, Hein K, Haman K, McNamara ME, Weaver C, Martinez A, Notsu H, Zieve G, Armstrong CC. Can integrating the Memory Support Intervention into cognitive therapy improve depression outcome? Study protocol for a randomized controlled trial. Trials. 2017 Nov 14;18(1):539. doi: 10.1186/s13063-017-2276-x.
Results Reference
derived
PubMed Identifier
27089159
Citation
Harvey AG, Lee J, Smith RL, Gumport NB, Hollon SD, Rabe-Hesketh S, Hein K, Dolsen EA, Haman KL, Kanady JC, Thompson MA, Abrons D. Improving outcome for mental disorders by enhancing memory for treatment. Behav Res Ther. 2016 Jun;81:35-46. doi: 10.1016/j.brat.2016.03.007. Epub 2016 Apr 2.
Results Reference
derived

Learn more about this trial

Improving Depression Outcome by Enhancing Memory for Cognitive Therapy

We'll reach out to this number within 24 hrs